Olivier Jarry Email & Phone Number

New York, Ny, Us

Santiago De Compostela, Galicia, Es

Supporting the organization and development of this pre-clinical oncology company that has patented the MPN Technology for the actively-targeted delivery of biologics (and small molecules) to tumor and metastatic cells, and even more importantly to intracellular oncoproteins (such as KRAS), until now considered "undruggable". Several assets co-developed with global pharma and biotech companies.

Miami, Florida, Us

ADvantage Therapeutics is developing therapies to treat neurodegenerative conditions with a major focus on Alzheimer’s Disease (AD). We are currently preparing for clinical trials in Europe and in the US. Furthermore, ADvantage is developing potentially paradigm-changing therapies to treat AD in its labs at the Vienna BioCenter.

Woburn, Massachusetts, Us

Rational Vaccines develops therapeutic and prophylactic vaccines against herpes simplex viruses HSV-1 and HSV-2. These vaccines are based on engineered live attenuated viruses designed for safety and immunogenicity. 4+ billion individuals are estimated seropositive to herpes, which may manifest itself as breakouts, neuropathy or even encephalopathy. Studies have linked HSV-1 to brain inflammation and neurodegeneration.

New York, Ny, Us

OS Therapies (OST) is a clinical-stage cancer immunotherapy company dedicated to developing a new way of activating the immune system to kill cancers that express HER2 like Osteosarcoma, Breast Cancer, Colorectal Cancer and other solid tumors. With over 30 years of without new treatments in Osteosarcoma, we are first addressing this urgent need for innovative therapies for both kids and adults.We will then expand our lead candidate’s therapeutic development into Breast, Esophageal, Lung, Ovarian, and Pancreatic cancers.

New York, New York, Us

Atlas Advisors provides its clients with advisory capabilities across North America, Europe, Latin America and Asia.Drawing on the deep and broad experience of our professionals, we are active across the full range of M&A advisory roles, including acquisitions, mergers, joint ventures, minority investments, asset swaps, divestitures, distressed sales, capital raising and financing from strategic and financial investors.

New York, Ny, Us

Arlington, Va, Us

Larchmont, New York, Us

- PHYSICIAN ENGAGEMENT. Processes and systems to develop physicians personally and professionally.- PATIENT ENGAGEMENT. Processes and systems to improve health outcomes and satisfaction for patients, while containing costs for the healthcare system ("triple aim").- ACCESS TO HEALTHCARE. Design and implement programs to increase access to healthcare for low income patients (GSK, Pfizer). Public-Private Partnerships (PPP). Collaboration with Non-Governmental Organizations (NGOs). Co-author of access to medicines study (http://www.medicines-for-bop.net/report/) with www.endeva.org and the German Government, and of a white paper about branded generics with Accenture.- BUSINESS DEVELOPMENT & STRATEGY CONSULTING. Angel Investor and coach for biopharma/biotech start-ups. Evaluation and due diligence for acquisitions and divestitures in biotech and medtech. Post-Merger Integration (with www.MergerWorks.com). International Commercialization and Market Access consulting (Americas, Europe, China). “Beyond The Pill” / Integrated Care strategies. Digital health.

Boston, Massachusetts, Us

New York, New York, Us

Launched B2B channels for Dario: Employers, Payers, Healthcare Providers, Drugstores, as well as several alliances with large organizations.

New York, New York, Us

DarioHealth Corp. (NASDAQ:DRIO) is a leading Global Digital Therapeutics (DTx) company revolutionizing the way people with chronic condition manage their health.By delivering personalized evidence-based interventions that are driven by precision data analytics, high quality software, and personalized coaching, DarioHealth has developed a novel approach that empowers individuals to adjust their lifestyle in a unique and holistic way.

Investment banking in biotechnology, medical technology, digital health. (FINRA registered Series 7, 63, 79)

Cambridge, Gb

LIFNano Therapeutics was founded in 2013 as a spin-out from the University of Cambridge, progressing to a clinical stage Nano-Bio-Med company specifically focused on targeted delivery of the biologic, Leukaemia Inhibitory Factor (LIF).Following the Founder's discovery that LIF is of profound importance in immune self-tolerance in addition to the known key role of LIF in stem cells and tissue maintenance, the therapeutic potential of LIF has been harnessed by invention of a targeted delivery platform using nanotechnology in collaboration with Yale University. After extensive proof of concept that our nano-formulated LIF is safe and efficacious, LIFNano Therapeutics is now taking LIF to patients. CEO 2016-2018

Cambridge, Gb

Stamford, Ct, Us

Strategic Planning. Health economics. Outcomes studies (retrospective, prospective, predictive). Value of diagnostics.

New York, New York, Us

Business development.

New York, Ny, Us

Expanding internationally a universe of social networks that allow verified healthcare professionals to collaborate with each other within their medical specialty, and life sciences companies to engage in a dialogue with them.Exit via divestiture to Informa plc.

Germantown, Maryland, Us

"Whether engineering novel therapies for health, delivering unique solutions to address global energy demand, enabling unparalleled productivity advancements in food, or developing innovative applications in the consumer and environment sectors, Intrexon is working diligently today to create a better tomorrow.”

Lawrence Township, Nj, Us

- Led Commercial Operations for a USD 1 billion division with fast growing, innovative medicines- Updated 10-year strategy for exponential growth. Local alliances and acquisitions. - Evaluated new pricing approaches such as tier pricing and enhanced Patient Accessibility Programs (PAPs).- Re-launched the Market Access function for Emerging Markets - Oncology, Virology, Immunology, Metabolism, CVS and CNS. Introduced or strengthened Patient Support Programs in cooperation with local third parties in several countries.- Turkey and Russia. Supported strengthening Market Access function and strategies to address forced price reductions in Turkey and regulations severely limiting access to HCPs in both countries.- Brazil. Redefined 5-year plan, reorganized Market Access in Brazil, supported public-private partnerships. Prepared the teams for numerous launches within 18 months.- India. Refined strategy and access based on new challenges (compulsory licensing threats, PAPs, discounts based on income, micro finance).- China. Defined 2021 vision with country president and team.

Leverkusen, North Rhine-Westphalia, De

- Led sustainable, profitable growth in all regions for a USD 1.5 billion business unit. Evaluated new ways to reach the market / create new market segments. Aligned the portfolio of products and services to new strategies. Explored possible partnerships, alliances, acquisitions. Adapted the talent pool.- Launched five acclaimed (New York Times, Wall Street Journal) new products and gained market share in most markets. - Introduced Market Access methodology (derived from Pharma) to prepare for the global launch of a new Continuous Glucose Monitoring (CGM) device.- Negotiated and implemented a new alliance with Medtronic to jointly access users of insulin pumps.- North America. Re-evaluated profitability by channel. Established new guidelines for negotiation with Payers. Engaged with US FDA on blood glucose meters accuracy standards.- Europe. Became #2, passing Johnson & Johnson.- Asia. Re-organized China and the region. Supported expansion to South East Asia through distributors.- Led plan to drastically reduce costs in all areas and re-structure the entire business, in coordination with Division President.

Basel, Baselstadt, Ch

- Grew the vaccines market share in more than 30 countries. Addressed the requests for H1N1 pandemic flu vaccines from numerous governments.- Restructured the region for its next phase of growth, including new launches, while maintaining internal headcount to the minimum.- Created regional Market Access function. Designed Market Access methodology derived from the Novartis Pharma methodology.- Supported Access teams regarding seasonal and pandemic flu across the region. Personally involved with several government for their procurement of H1N1 pandemic flu vaccine.- Directly negotiated Access for a "pre-market-approval" vaccine to address a meningitis outbreak. - Created Access for a new, sensitive tuberculosis test in Russia, in collaboration with local hospitals.- Prepared local teams for rapid growth. Organized new management teams in strategic countries. Expanded partnerships with distributors. Analyzed opportunities for external growth and partnerships. Anticipated the launch of future “blockbuster” products.

Basel, Baselstadt, Ch

- Designed and implemented a then unique for-profit business model to improve access to medicines in low-income markets of rural India, a CEO-backed initiative involving new products, new distribution, face-to-face marketing, alliances with NGOs and local healthcare players. (http://www.youtube.com/watch?v=o6nS8gBM_WQ)- Introduced 70 medicines in 9 therapeutic areas, along with awareness / affordability / availability programs. Led the design of several products specifically for this channel.- After two years, 25 million villagers were served in more than 50 locations throughout four Indian states, with medicines addressing conditions from anemia to tuberculosis- Participated in shaping a new division to better address developing countries.

Basel, Baselstadt, Ch

- Supported the growth of a USD 1.5 billion division through M&A, JV's, alliances, various agreements (co-manufacturing, technology in- and out- licenses, distribution...)- Developed strategic plans for division and group executive committees, that ultimately led to a divestiture of the division to Nestlé. - Managed Asia region. Created or expanded partnerships in China and Japan to facilitate local manufacturing and marketing of baby nutrition products and baby accessories.- Led Consumer Excellence for the Division, the marketing best practices and development program of Novartis Consumer Health

Basel, Baselstadt, Ch

- Grew all markets in Latin America (US$ 250 million – baby jars and cereals, baby accessories) and achieved record market shares in each country and segment, despite a very depressed economy in the continent, falling consumer purchasing power, diminishing births and intensified competition - Simplified organization from 7 sub-regions to 3 and implemented leaner organization (3000 associates, 4 plants). Simplified product portfolio. Expanded partnerships (Disney).- Worked with Mexican MOH to optimize supplementation in baby nutrition and obtain an endorsement from pediatrician associations. Designed low-price cereals and purees for low income segment (under new brand). As a result, sales from new products soared, changing category dynamics from -13% to +14% in traditional stores.

Basel, Baselstadt, Ch

- Developed all Consumer Health activities in Argentina, Brazil, Chile, Paraguay, Uruguay (US$100 million – baby products, over-the-counter (OTC) drugs, medical nutrition, functional foods).- Turned around the Brazilian business after years of losses. Consolidated plants. Divested non-core businesses. Grew Medical Nutrition and OTC businesses by mid-double-digit with new, local manufacturing of liquid ready-to-use nutrition product, pain management spray and patch.

Basel, Baselstadt, Ch

Defined, organized and ran the 2002-2006 worldwide Strategic Plan for the Division (US$ 6 billion). Led numerous projects of acquisitions, divestitures and licensing (Poland, Brazil, Germany, France).

Paris, Fr

Coordinated the 2001-2005 Strategic Plan for the Worldwide Water Division (US$ 3 billion) and defined global strategies. Initiated and led alliances and acquisitions in Canada, the USA, Mexico, Brazil, Uruguay, Argentina, Portugal and Italy.

Paris, Fr

Contributed to grow the US and Canadian sales from US$ 250 millions to US$ 600 millions through organic growth and 3 successfully integrated acquisitions (AquaPenn Spring Water, McKesson Water Products, Naya)

Dublin 2, Ie

- Sold, designed and implemented consulting engagements related to major transformations in multinational companies, predominantly in the mechanical and electronics industries (strategic analysis, business process reengineering (BPR), design and implementation of information systems, change management, M&A). Specialized in profitability turnaround, mergers & acquisitions, launch of new activities- DANONE. Creation of the International Division, selling in 65 countries.- GENERAL ELECTRIC MEDICAL SYSTEMS - EUROPE. Reengineering of Finance and Business Planning into a single location for all European operations, saving very significant costs.- SCHNEIDER ELECTRIC. Post-Merger Integration (PMI) of 6 acquisitions worldwide. Global design and implementation of a new worldwide strategic planning and business planning process, of a new cost accounting system .Reorganization of the German subsidiary.- SNCF (French Railways). Led the 1995-2000 Strategic Plan (“Contrat de Plan”, USD 20 billion investments - approved by the Minister of Transportation and implemented in the following years).- UNION CARBIDE (Graphite Division). Worldwide reorganization. Reengineering of Manufacturing, Sales and Finance. 1993 Strategic Plan. The division maintained its global #1 position.- Other major clients: Automotive & Aerospace: Dassault Aviation, EADS (Aerospatiale, Matra), Hispano-Suiza, KHD, Matra Automobile, Renault, SNECMA, ICI. Electronics: Alcatel, Bull, Hewlett-Packard. Oil & Gas: AGIP, Elf. Other Manufacturing: Alsthom Atlantique, Cabot (Carbon Black), Carnaud Metalbox, Schindler. Services: Aéroports de Paris, Electricité de France, La Redoute Catalogue, Ministère de l’Equipement, SITA.

Paris Cedex 15, Cs 21623, Fr

Supported 3-star General Sandeau at DGA/DTEn in his mission of evaluating and procuring defense systems.

Fr

Scientifique du Contingent (Engineer) - French Air Force

Master Of Business Administration (M.B.A.), Executive Mba, International Business

Executive Mba, International Business

Emba, International Business

Emba, International Business

Master Of Engineering - Meng, Defense Systems

Msc, Aerospace